Roche Raises Cholesterol Profile With HDL-C Elevator From Japan Tobacco

Japan Tobacco’s JTT-705 is in Phase II for treatment of dyslipidemia by raising levels of HDL cholesterol. Roche’s license for the drug puts the company second to Pfizer in the race to market a cholesteryl ester transfer protein inhibitor.